HERZLIYA, Israel and CALGARY, AB , May 28, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the " Company " or " Innocan "), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies is pleased to announce its financial consolidated results for the first quarter ended March 31, 2025 , and provides a corporate update on its recent activities and... Read More

Innocan's first fully-granted patent in Mexico Covers Innocan's proprietary cannabis-based pain relief topical Indication of Innocan's growing intellectual property portfolio HERZLIYA, Israel and CALGARY, AB , May 6, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the Mexican... Read More

HERZLIYA, Israel and CALGARY, AB , April 15, 2025 /CNW/ -- Innocan Pharma Corporation (the " Company ") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has closed its previously announced non-brokered private placement offering (the " Offering ") of units of the Company (the " Units "), pursuant to which the Company issued 1,193,551 Units at a price of $0.18 per Unit (the " Offering Price ") for... Read More

Innovative Chronic Pain Treatment expand IP Protection in China's US$163 Billion Pharmaceutical Market HERZLIYA, Israel and CALGARY, AB , April 7, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that a divisional application for its Chinese (CN) liposome-based CBD technology patent... Read More

HERZLIYA, Israel and CALGARY, AB , March 31, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the " Company " or " Innocan "), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies is pleased to announce its audited financial consolidated results for the year ended December 31, 2024 . Full Year 2024 Financial Highlights Revenues increased 114.6%... Read More

HERZLIYA, Israel and CALGARY, AB , March 7, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the " Company " or " Innocan ") is pleased to announce that it has closed its previously announced non-brokered private placement offering of a debenture unit of the Company (the " Debenture Unit ") to its largest shareholder, Tamar Innovest Ltd. (" Tamar Innovest ") for gross proceeds of US $1,000,000... Read More

HERZLIYA, Israel and CALGARY, AB , Feb. 27, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the " Company " or " Innocan ") is pleased to announce that it intends to complete an offering of a debenture unit of the Company (the " Debenture Unit ") to its largest shareholder, Tamar Innovest Ltd. (" Tamar Innovest ") for gross proceeds of US $1,000,000 (the " Offering "). The Debenture Unit... Read More

This is the second successful treatment in a donkey, demonstrating the potential of Innocan's Liposomal CBD injection for human and veterinary use HERZLIYA, Israel and CALGARY, AB , Feb. 10, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the... Read More

HERZLIYA, Israel and CALGARY, AB , Jan. 29, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that its subsidiary, BI Sky Global (BI), successfully completed the Human Repeated Insult Patch Test (HRIPT) for Sensitization and Irritation Testing, ensuring the safety of its cosmetic... Read More

HERZLIYA, Israel and CALGARY, Alberta , Jan. 9, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA's Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver for its LPT-CBD (Liposome Platform Technology-Cannabidiol) product for the second... Read More

HERZLIYA, Israel and CALGARY, AB , Dec. 31, 2024 /CNW/ -- Innocan Pharma Corporation (the " Company ") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has closed its previously announced non-brokered private placement offering (the " Offering ") of units of the Company (the " Units "), pursuant to which the Company issued 3,177,223 Units at a price of C$0.20 per Unit (the " Offering Price ") for... Read More

HERZLIYA, Israel and CALGARY, AB , Dec. 19, 2024 /CNW/ -- Innocan Pharma Corporation ( CSE : INNO ) ( FSE : IP4) (OTC: INNPF ) (the " Company " or " Innocan ") is pleased to announce that it intends to complete a non-brokered private placement of up to [3,500,000] units of the Company (the " Units ") at a price of [ C$0.20 ] per Unit for gross proceeds up to C$700,000 plus 15% over allotment options (the "Offering"). The... Read More

HERZLIYA, Israel and CALGARY, Alberta , Dec. 12, 2024 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and an owner of a proprietary intellectual property portfolio, is pleased to share its annual "State of Research and Development" update for 2024. This year, the... Read More

HERZLIYA, Israel and CALGARY, AB , Nov. 26, 2024 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to report positive results from a basic safety assessment study, evaluating LPT-CBD administered as a single injection in Göttingen minipigs. The drug was administered in three ascending doses, and the... Read More

2.7X Revenue Growth Year-Over-Year at US $24 Million for 9-month Period HERZLIYA, Israel and CALGARY, Alberta , Nov. 20, 2024 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform... Read More

A recent National Pet Owners Survey demonstrates a significant addressable market for Innocan's veterinary product HERZLIYA, Israel and CALGARY, AB , Nov. 11, 2024 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, announced that it has taken the strategic decision to focus its development resources on advancing... Read More

HERZLIYA, Israel and CALGARY, Alberta, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in chronic pain management via Liposomal CBD drug products, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional... Read More

HERZLIYA, Israel and Calgary, AB , Oct. 16, 2024 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in chronic pain management via Liposomal CBD drug products, is pleased to announce that it will be presenting at the 2024 ThinkEquity Investor Conference taking place on October 30 at the Mandarin Oriental Hotel in New York, NY . The Company will be discussing its... Read More

HERZLIYA, Israel and CALGARY, Alberta , Oct. 11, 2024 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce promising results from a multi-year compassionate therapy using repeated liposomal-CBD (LPT-CBD) injections for pain relief in dogs with naturally-occurring osteoarthritis. The therapy... Read More

HERZLIYA, Israel and CALGARY, Alberta , Oct. 9, 2024 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that Dr. Joseph V. Pergolizzi, Jr. , M.D., a member of Innocan's Scientific Advisory Board, has been recognized among the top 2% most-cited scientists in the world in a new list... Read More

HERZLIYA, Israel and CALGARY, Alberta , Sept. 3, 2024 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that it has received a positive response from the U.S. Food and Drug Administration (FDA) following Innocan's successful pre-Investigational New Drug (pre-IND) Type B meeting with the... Read More

HERZLIYA, Israel and CALGARY, Alberta , Aug. 29, 2024 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that it has completed its previously announced non-brokered private placement offering of 5,025,725 units of the Company (the "Units") at a price of C$0.22 per Unit for gross proceeds... Read More

Innocan Pharma Announces Private Placement HERZLIYA, Israel and CALGARY, Alberta , Aug. 22, 2024 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that its subsidiary, BI Sky Global (BI), successfully completed the registration of all its products under the FDA's Modernization of... Read More

HERZLIYA, Israel and CALGARY, AB , July 26, 2024 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA's Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver and assigned an Investigational New Animal Drug (INAD) number for its LPT-CBD (Liposome... Read More

HERZLIYA, Israel and CALGARY , Alberta , July 2, 2024 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that it has engaged Past-President of the Eastern Pain Association, Dr. William K. Schmidt , to support its LPT-CBD submission process to the FDA for chronic pain. "We are thrilled to... Read More

HERZLIYA, Israel and CALGARY, AB , June 11, 2024 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the success and conclusion of a preliminary safety evaluation of Innocan's single injection and sustained-release LPT-CBD conducted on minipigs. The animals demonstrated excellent drug... Read More

HERZLIYA, Israel and CALGARY, AB , May 27, 2024 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce its consolidated financial results for the three-month period ended March 31, 2024 . First Quarter 2024 Financial Highlights Revenues increased 334%... Read More

The regulatory approval process with the U.S. Food and Drug Administration has commenced for Innocan's LPT-CBD release technology, marking a key step in the advancement of non-opioid pain management HERZLIYA, Israel and CALGARY, AB , May 21, 2024 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), is pleased to announce significant advancements in the regulatory process for... Read More

HERZLIYA, Israel and ALGARY, AB , May 9, 2024 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the successful pre-clinical treatment with a liposomal-CBD injection in a female donkey. Innocan's innovative therapy provided immediate noticeable pain relief and improved mobility. Miri, a... Read More

With its submission of a Pre-IND Meeting Request Letter, Innocan initiates the regulatory process with the U.S. Food and Drug Administration (FDA) for the approval of its prolonged CBD release technology for human use HERZLIYA, Israel and CALGARY, AB , April 22, 2024 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), is pleased to announce that is has reached a key... Read More

HERZLIYA, Israel and CALGARY, Alberta , April 1, 2024 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies is pleased to announce its audited financial consolidated results for the year ended December 31, 2023 . Full Year 2023 Financial Highlights Revenues increased 534%... Read More

HERZLIYA, Israel and CALGARY, AB , March 25, 2024 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the development of drug delivery technologies using CBD for the pharmaceutical and biotechnology industries, is pleased to announce the signing of an agreement with the Hebrew University , which facilitate Innocan to initiate the Food and Drug Administration... Read More

HERZLIYA, Israel and CALGARY , Alberta , March 14, 2024 /CNW/ -- Innocan Pharma Corporation (the " Company ") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has closed its previously announced non-brokered private placement offering (the " Offering ") of units of the Company (the " Units "), pursuant to which the Company issued 7,952,840 Units at a price of $0.25 per Unit (the " Offering Price ") for... Read More

Innocan Announces Notice of Intention to Complete a Private Placement of Units HERZLIYA, Israel and CALGARY, Alberta , March 5, 2024 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the development of drug delivery technologies using CBD for the pharmaceutical and biotechnology industries, is pleased to announce the following: Recent Tissue Distribution... Read More

HERZLIYA, Israel and CALGARY, AB , Feb. 26, 2024 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the latest findings from the Company's pharmacokinetic study of its LPT-CBD platform in rabbits. The fundamentals of LPT-CBD lay in its ability to slowly release CBD into the blood stream.... Read More

HERZLIYA, Israel and CALGARY, Alberta , Dec. 12, 2023 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce establishment of a specialized team to prepare the Company's submission to the United States Food and Drug Administration (the "FDA") for the human application of its LPT CBD platform.... Read More

HERZLIYA, Israel and CALGARY, Alberta , Nov. 3, 2023 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the company's latest groundbreaking findings. Animals were injected every several weeks with LPT-CBD over a period of 6 months, and showed: Good tolerance of the drug. Consistently... Read More

HERZLIYA, Israel and CALGARY, Alberta , Oct. 23, 2023 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the company's latest groundbreaking findings. Research over the past several months has identified animals that metabolize cannabidiol (CBD), administered as a liposomal CBD injection,... Read More

HERZLIYA, Israel and CALGARY, Alberta , Oct. 20, 2023 /CNW/ -- Innocan Pharma Corporation (" Innocan " or the " Company ") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has closed the second and final tranche (the " Second Tranche ") of its previously announced private placement offering (the " Offering ") of units of the Company (the " Units "), pursuant to which the Company issued 4,005,408 Units at... Read More

HERZLIYA, Israel and CALGARY, Alberta , Oct. 12, 2023 /CNW/ -- Innocan Pharma Corporation (the " Company ") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has closed the first of two tranches (the " First Tranche ") of its previously announced private placement offering (the " Offering ") of units of the Company (the " Units "), pursuant to which the Company issued 1,420,200 Units at a price of $0.30... Read More

HERZLIYA, Israel and CALGARY, Alberta, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Innocan Pharma Corporation (the “ Company ”) (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has entered into an agreement with Research Capital Corporation as the sole agent and sole bookrunner (the “ Agent ”) on a “best efforts” agency basis in connection with a marketed private placement offering (the “ Offering ”) of units of... Read More

HERZLIYA, Israel and CALGARY, AB , Sept. 15, 2023 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pioneering pharmaceutical technology company specializing in innovative wellness products, is elated to announce the appointment of Dr. Joseph V. Pergolizzi, Jr. , M.D. to its Scientific Advisory Board (SAB). Dr. Pergolizzi, a distinguished expert in the field of pain... Read More

Innocan hair care cream efficacy trial observes enhanced hair growth in male and female participants in a 14day period. 91 % of participants reported stronger hair and 100% of participants reported reduced hair loss The trial, revealed significant hair growth improvements. These promising results further expand Innocan's... Read More

HERZLIYA, Israel and CALGARY, AB , Aug. 29, 2023 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce the results of a clinical study regarding the pain-relieving effects and safety of the Company's subcutaneous liposomal CBD (Innocan's LPT platform) for... Read More

US$3.121M Revenues for Q2, 2023 compared to US$415,000 for Q2 2022, representing an increase of 652% US$2.656M Gross Profit for Q2, 2023 compared to USD 214,000 for Q2 2022, representing an increase of approximately 1,141% HERZLIYA, Israel and CALGARY, AB , Aug. 25, 2023 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on... Read More

HERZLIYA, Israel and CALGARY, AB , Aug. 15, 2023 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company specializing in innovative wellness products, today unveiled the successful results of a controlled efficacy trial (the "Trial") of their diabetic foot relief cream (the "Product"). The Trial results affirm that Innocan's Product - a... Read More

HERZLIYA, Israel and CALGARY , Alberta , Aug. 4, 2023 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the " Company " or " Innocan ") is pleased to announce that it has today closed a non-brokered private placement offering of 8,409,735 units of Innocan (the " Units ") at a price of C$0.23 per Unit for aggregate gross proceeds of C$1,934,239 (the " Offering "). Each Unit consists of: (i) one (1)... Read More

USD 1.4M Gross Profit, compared to USD 78K last year USD 4.1M Cash Balance along the entire corporate structure USD 1.3M Increase in Revenues Compared to Q1 2022 HERZLIYA, Israel and CALGARY, AB , May 31, 2023 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner... Read More

HERZLIYA, Israel and CALGARY, Alberta , May 8, 2023 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a leading pharmaceutical and biotech company, is pleased to announce the successful treatment of Billy, a 4-year-old neutered male goat, with a liposomal-CBD injection in a pre-clinical trial. The innovative therapy provided much-needed relief to the animal, born with... Read More

HERZLIYA, Israel and CALGARY, AB , May 1, 2023 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce the entering into of a wide-scope commercial distribution agreement with UAB Medexy ("UAB Medexy") (the "Distribution Agreement"). As part of the... Read More

HERZLIYA, Israel and CALGARY, Alberta , April 18, 2023 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is pleased to report its audited financial results for the year ended December 31,2022 . Additional information concerning... Read More

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - March 23, 2023) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative wellness products, announced today the successful results of a controlled efficacy test (the " Trial ") regarding its vaginal derma product (the " Product "). The results of the Trial... Read More

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - March 17, 2023) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is excited to announce the launch of its licensing and commercialization strategy work with respect to... Read More

This is the first fully granted patent of Innocan in the United States The Patent covers Innocan's proprietary cannabis-based pain relief topical This serves as an indication of Innocan's growing intellectual property portfolio Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - March 12, 2023) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology... Read More

"Lady", an 11-year-old female dog was presented to Innocan labs suffering from severe autoimmune mediated polyarthritis. Lady was treated with Glycoflex, steroids, and hydrotherapy, but still suffered pain and had difficulty walking more than a few steps. Lady was administered Innocan's liposomal CBD injection and experienced... Read More

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - February 16, 2023) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is pleased to report an annual "State of the Business" update, including with respect to the company's... Read More

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - December 2, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce that it has signed a consulting agreement with Benitz Consulting LLC ("Benitz Consulting") to assist the Company's... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is pleased to report its financial results for the three and nine months ended September 30, 2022. "We delivered encouraging results in the third quarter, with revenue growth and are... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is pleased to announce the addition of Givi Topchishvili, to Innocan's Advisory Committee, as a business strategy adviser, focused on commercializing of healthcare innovations. Givi... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is pleased to announce the successful implementation of Priority Software's Priority™ Enterprise Resource Planning (ERP). The new Priority™ ERP system includes financial, logistics, and... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is pleased to announce its participation in a webinar titled "Investor Day: Companies Disrupting The World We Live In", co-hosted by IR Labs Inc . ("irlabs") and the NEO Exchange. The... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the “Company” or “Innocan”) a pharmaceutical tech company focusing on developing innovative drug delivery platform technologies comprised with cannabinoids (CBD) is pleased to announce that it will be participating in the Luxury Meets CBD Conference (LMCC) Fall 2022, on October 20th and 21st in New York where Innocan will showcase its patent pending topicals... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical tech company focusing on developing innovative drug delivery platform technologies comprised with cannabinoids science, is pleased to report an additional milestone with respect to Innocan patent application: PCT application WO2021/240505 that claims Cannabinoids Based Topical Compositions for Treatment of Psoriasis... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical tech company focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, is pleased to provide the following operational update on its key lines of business: Recent development: We are happy to announce that the PCT title as " CANNABIDIOL-CONTAINING COMPOSITIONS AND USES... Read More

A 4-year-old intact male border collie dog with a body weight of 22 kg was suffering from refractory idiopathic (drug-resistant) epilepsy The dog was frequently hospitalized to stop seizure clusters Following treatment using Innocan's LPT (CBD Loaded Liposome Platform), seizures stopped for 9.5 weeks Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical tech company focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, today announced that Iris Bincovich CEO of Innocan Pharma, will participate in the H.C. Wainwright 24 th Annual Global Investment Conference to be held at the Lotte New York Palace Hotel in New York... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to report its financial results for the quarter ended June 30, 2022. Second Quarter 2022 Financial and Operating Highlights (unaudited): Cash balance at end of Q2-22 - USD 7.7M, in Q2-21 - USD 4.6M, an increase of approximately of 70% from the corresponding quarter. Revenues in Q2-22 - USD 415 thousand compared to Q2-21 -... Read More

6 dogs suffering from osteoarthritis and lameness demonstrated CBD concentrations 6 weeks after a single injection Pain and well-being scores improved following treatment Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce positive partial results in a pilot pain study in dogs using the LPT CBD Liposomal Delivery Platform. Six dogs suffering from osteoarthritis... Read More

First results from a study on dogs showed close to 100% bioavailability of CBD using Innocan's LPT technology This is compared to 6.5-20% bioavailability in humans when administered orally Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce results that approached 100% bioavailability following subcutaneous injection of its CBD proprietary LPT delivery system... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it has filed a new patent application (PCT) entitled "compositions for treatment of hair loss", claiming priority from an earlier US provisional patent application. The composition developed by Innocan research and development and disclosed in the current PCT can be used to treat and prevent hair loss and... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it has filed a new patent application (PCT) entitled "compositions for treatment of diabetic symptoms", claiming priority from an earlier US provisional patent application. This application contributes to Innocan's continued expansion of its health and wellness intellectual property portfolio of 14 patent... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it has appointed Nissim Vasilevski as Analytical Chemist. In this role, Mr. Vasilevski will join the team developing analytical methods to accelerate this critical development and validations of Innocan Pharma's liposome platform technology (LPT) product line, with a view to reaching human clinical trials... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce positive results in a preclinical trial involving a dog with refractory (drug-resistant) epilepsy. In this trial, the dog was treated with Innocan Pharma's LPT (CBD Loaded Liposome Platform) injections. The... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce successful preclinical trials in dogs with osteoarthritis. A case entailing the clinical condition of Goody, an 8-year-old male mixed-breed dog, who was rescued in a terrible condition after he was found tied up... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it has filed a new PCT patent application entitled "Compositions for Treatment of Vaginal Atrophy" on June 12, 2022, claiming priority from a US provisional patent. Vaginal atrophy is a condition associated with loss of moisture, thinning, and inflammation of the vaginal walls, which can be associated... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce the successful preliminary results of a small-scale efficacy trial in dogs with refractory (drug-resistant) epilepsy. In this initial phase, the dogs were treated with Innocan Pharma's LPT (CBD Loaded Liposome Platform) injection. The results demonstrate that these dogs had a decrease in the frequency of their... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is proud to report its financial results for the quarter ended March 31, 2022. First Quarter 2022 Financial and Operating Highlights: Cash balance at end of Q1-22 - USD 9.5M, in Q1-21 - USD 4.4M, an increase of approximately of 215% from corresponding quarter. Net loss for Q1-22 - USD 0.7M. Net loss in Q1-21 - USD 4.8M, a decrease... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the " Company " or " Innocan ") is pleased to announce that it has filed and obtained a receipt for a final short form base shelf prospectus (the " Base Shelf Prospectus ") with the securities regulatory authorities in each of the provinces and territories of Canada. The Base Shelf Prospectus allows Innocan to qualify the distribution of up to $100,000,000 of... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that an International Patent Application ("PCT") titled "Protein-bound Cannabinoid Formulations and Uses Thereof" was recently published and received the publication number WO 2022/070191 (the "Patent... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is proud to announce the publication of a case report regarding its compassionate care liposomal-CBD formulation (Innocan's LPT platform) (the " Treatment "). The Treatment was administered to a 14-year-old dog suffering from severe... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to report the "accepted for publication" of a Case Report Article describing subcutaneously injected liposomal cannabidiol (CBD) formulation used as a compassion therapy for pain management in a dog. The final article will be published in the Frontiers Veterinary Scientific Journal, a leading and renowned journal with... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), is pleased to report the successful completion of Innocan's CBD Liposome drug-product physico-chemical characterization. Physico-chemical characterization is an important part of the application package to be submitted to the FDA. It is also a crucial milestone towards a potential submission of an Investigational New Drug Application... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the " Company " or " Innocan "), is pleased to announce that Innocan's CBD LPT injection provided as a treatment to a dog suffering from osteoarthritis of the hip and elbow joint (causing inability of the dog to walk and stand up, as well as intense pain and a low activity rate) led to a decrease in pain and improved activity and vitality, as reported by the... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce the appointment of Dr. Eyal Kalo as Research and Development Project Manager. In this new role Dr. Eyal Kalo will coordinate internal and external R&D projects, assist in the development progress and manage the cross functional of Innocan's pharma projects. About Dr.Eyal Kalo Dr.Eyal Kalo earned his PhD from... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce the addition of Dr. Kenji Kitatani, a leading global media business expert, and former Executive Officer of Sony Corporation, to Innocan pharma's Advisory Committee, as an advisor to the Asian markets. The popularity of CBD products in Japan is growing rapidly . Combined with the growing admiration to natural... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the " Company " or " Innocan "), is pleased to provide an update on its research into CBD loaded liposomes using Innocan's LPT platform. Innocan's core goal is to develop a technology that combines the advantages of two well-known drug and delivery system to... Read More

Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the agenda for the upcoming Cannabis Industry Virtual lnvestor Conference. Individual investors, institutional investors, advisors and analysts are invited to attend. The two-day program begins at 11:00 AM ET on Wednesday, January 19 th . It is recommended that investors pre-register and run the online system check to expedite... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the " Company " or " Innocan ") is pleased to announce that it has inaugurated its first and new drug research and development lab at Biohouse Labs at Hadassah Medical Center in Jerusalem to accelerate the Company's liposome Platform Technology ( LPT ) development. The Company's development program is focused on improving and optimizing LPT characterization... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the " Company " or " Innocan "), is pleased to announce a second amendment (the " Amendment ") to the research and license agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (" Yissum ") for the performance of studies evaluating the efficacy of its CBD-Loaded Liposome Platform Technology (LPT) in treating dogs. The... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the " Company " or " Innocan "), is pleased to announce today that after the early substantial positive results of its CBD Loaded Exosome Platform (CLX), its Company's wholly-owned subsidiary, InnoCan Pharma Ltd. ("InnoCan Israel"), has signed a Research and License Agreement (the "New Agreement") with Ramot, the Technology Transfer Company of Tel Aviv... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the " Company " or " Innocan "), is pleased to announce that in its recent study of its CBD-loaded liposome technology (LPT) on dogs, CBD showed prolonged plasma concentrations for at least six weeks after a single administration. These results are significant... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce that CEO Iris Bincovich will be participating in the Industry Day Main Panel at the Lift & Co. Expo, on November 19, 2021, in Toronto. The panel, titled "Business Growth Update: Canadian Business for today's... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the " Company " or " Innocan "), is pleased to report further progress in the Cannabinoids loaded Exosome Delivery Platform (CLX) research. The researchers at Prof. Offen's laboratory at the Tel Aviv University, have succeeded to characterize the profile of the... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan) is pleased to announce that all investors who participated in the Company's December 2020 private placement (the "Offering") fully exercised the common share purchase warrants (the "Warrants") issued to them as part of the Offering. The exercise of the Warrants by the investors resulted in a total cash receipt for the Company of... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the " Company " or " Innocan "), is pleased to announce that CEO Iris Bincovich will embark on a 2 day trip on October 29-30 to Munich, Germany with the purpose of meeting investors and potential clients. Ms. Bincovich will attend an open Q&A session that will take place in the Novotel München Messe, Willy-Brandt-Platz 1, 81829 München. Please RVSP at... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the " Company " or " Innocan "), is pleased to announce the results of a recent study showed the presence of Cannabidiol (CBD) in mice's brains, 41 days after being injected with Innocan's CBD LPT (CBD-Loaded Liposome Platform Technology). In contrast, no CBD... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the " Company " or " Innocan "), today announced that it has closed its previously announced private placement of the Company's common shares (a " Common Share " and, collectively, the " Common Shares ") and warrants to purchase common shares (" Common Warrants ") to institutional investors for aggregate gross proceeds to the Company of C$8,227,150 million... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the " Company " or " Innocan "), today announced that it has entered into securities purchase agreements for a private placement of the Company's common shares (a " Common Share " and, collectively, the " Common Shares ") and warrants to purchase common shares (" Common Warrants ") to institutional investors for aggregate gross proceeds to the Company of... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the " Company " or " Innocan "), is pleased to announce that a new patent application has been filed for Innocan's CBD Delivery System Technology, alongside the existing LTP (CBD Loaded Liposomes) and CLX (CBD Loaded Exosomes). The new patent application... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the " Company " or " Innocan "), hereby announces the filing by Ramot of a new patent application for a unique Cannabinoids exosome delivery platform - CLX, developed by Ramot and their researchers from Tel Aviv University. InnoCan holds worldwide exclusive... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the " Company " or " Innocan "), is pleased to announce that it has conducted a recent experimental study of its CBD-loaded liposome technology (LPT) on large animals that demonstrated a similar pharmacokinetic profile as was demonstrated in a previous small... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") reports today, that since January 1st, 2021, it has received proceeds of approximately CAD $8.2M as a result of the exercise of approximately 32.9 Million previously issued common share purchase warrants and broker warrants. As a result, over 94% of Innocan's Warrants dated back to June 2020 and over 95% of its September 2019... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce that, following the early indications of its CBD Loaded Exosomes platform (CLX), the Company has issued a notice to Ramot, the Technology Transfer Company of Tel Aviv University (TAU), declaring the Company's... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce its been engaged into a manufacturing and distribution agreement dated August, 2021 (the "Manufacturing and Distribution Agreement") with Ayurcann Inc. ("Ayurcann"), a major Health Canada licensed producer and distributor of CBD products. Pursuant to the terms of the Manufacturing and Distribution Agreement,... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to issue an update on its cutting-edge pre-clinical studies and on the development progress of its Liposome/CBD delivery platform (LPT). These studies are led by Dr. Ahuva Cern and Prof. Chezy Barenholz of The Hebrew University of Jerusalem. To date, Innocan completed two pre-clinical trials on animals. The first trial... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") filed a patent application for its topical composition for hair loss treatment. The patent application discloses and claims several compositions for topical administration comprising cannabinoid for the treatment and prevention of hair loss. Hair loss is the one of the most common syndromes faced by most of the people around the... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce the addition of Izhar Shay, Israel's former Minister of Science and Technology, and one of Israel's leading Venture Capitalists to its Advisory Committee. Izhar Shay was the Minister of Science and Technology in the 35th Government of the State of Israel until January 2021. Before that, he managed the... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") announces the filing of an international patent application for Topical Composition for the Treatment of Diabetic Symptoms. The patent application discloses and makes claims for several compositions for topical administration comprising of cannabinoid for the treatment of diabetic related conditions. Specifically, the compositions... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce that it has signed an exclusive distribution agreement with Health Investment Group S.A. ("HIG") for HIG to distribute Innocan's SHIR and Relief & Go brands in Poland. Poland's domestic cosmetic market is... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the " Company " or " Innocan "), is pleased to announce that it has completed a cosmetic clinical study of its SHIR ® CBD+ ANTI-AGING SLEEPING MASK. The study shows that women who tested the product experienced a reduction in the appearance of their lines and... Read More

Innocan Pharma (OTC: INNPF) (CSE: INNO) (FSE: IP4) based in Israel, focused on developing drug delivery platforms containing Cannabinoids today announced that Iris Bincovich, will present live at LifeSciencesInvestorForum.com on June 24 th . DATE: Thursday, June 24 th TIME: 10:30 AM ET LINK: https://bit.ly/3c7Ertp This will be an interactive online event where investors are invited to ask the company questions in real-time.... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the " Company " or " Innocan "), is pleased to announce today that it has completed a cosmetic clinical study of SHIR ® CBD Eye Serum on 22 volunteers. Roughly 54% of participants of the study showed a decrease of volume of the participants' eye bags of around... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is honored to announce it has filed an international patent application for a novel cannabis-based Vaginal Moisturizer and Lubricant Treatment. The composition comprises cannabinoids and additional agents of a phytoestrogen and hyaluronic acid and may be applied to alleviate vaginal dryness and vaginal atrophy. Vaginal moisturizers... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the " Company " or " Innocan "), is pleased to announce that a recent study conducted on mice demonstrated a prolonged release of cannabidiol (CBD) into the animals' bloodstream for at least 7 weeks following local two injections. Innocan believes this result to be extremely encouraging, given the 24-hour maximum CBD presence in the bloodstream when... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce that it will participate at the Lytham Partners Summer 2021 Investor Conference on June 14 through June 16, 2021. Iris Bincovich, CEO of Innocan will participate on the "CBD Treatments" discussion panel alongside representatives from cbdMD, Charlotte's Web, CV Science Inc, and Avicanna on Monday June 14 at... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the " Company " or " Innocan "), is pleased to announce today that a recent study conducted in mice based on Innocan's licensed CBD-loaded liposome platform technology (LPT) for injectable CDB solutions demonstrated a prolonged release of cannabidiol (CBD) into the mice's' bloodstream for at least 50 days following two injections. This study was led by Dr.... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") today announced it has retained Lytham Partners, LLC ("Lytham Partners") to lead an investor relations and shareholder communication program. For more than 20 years, Lytham Partners has been one of the industry's leading investor relations firms, having created one of the largest and most diverse networks of institutional investors,... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it is currently trading on the OTCQB Venture Market and is eligible for electronic clearing and settlement through The Depository Trust Company ("DTC") in the United States. The Company's common shares are... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce the signing of a wide-scope commercial distribution agreement with Polyflame Europe. As part of the multi-year agreement, Polyflame Europe will enjoy an exclusive right to distribute both of Innocan's SHIR and... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is proud to announce the addition of Richard Serbin to its Advisory Committee. Richard Serbin will work closely with Innocan's leadership to address the emerging global Pharma opportunities, to expand Innocan's presence as part of its growth strategy, and to contribute from his extensive experience as Johnson & Johnson's Executive... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the " Company " or " Innocan "), is pleased to announce today its financial results and business highlights for the fourth quarter and year period ended December 31, 2020 and provide highlights and comments on these results. This news release should be read in conjunction with the Company's audited financial statements for this period (the " Financial... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the "Company" or "Innocan") is proud to announce the addition of Dr. Mitchell Kline to its Scientific Advisory Committee. Dr. Kline will serve as an active member of Innocan's R&D team, using his extensive experience in researching and treating different skin conditions, to further develop Innocan's derma cosmetic line. Dr. Mitchell Kline is a... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the "Company" or "Innocan") today announces that since January 1, 2021, it has received proceeds of approximately CDN $3.1M as a result of the exercise of approximately 11.9 million previously issued common share purchase warrants (the "IPO Warrants") and certain broker warrants. Pursuant to the terms of the IPO Warrants, the Company's volume weighted... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the "Company" or "Innocan") filed an international patent application for a novel cannabis-based Anti-itch treatment. The composition is comprised of a pharmaceutically effective amount of a cannabinoid and active ingredients to aid in the relief of itching... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the "Company" or "Innocan"), is pleased to announce the completion of its first full and large-scale commercial production of its SYNONY premium cosmetic line and Relief &Go OTC pain relief spray in the United States and the launch of its US Commercial... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the "Company" or "Innocan") today announces that since December 1, 2020, it has received proceeds of approximately CDN $1.8M as a result of the exercise of approximately 7.6 Million previously issued common share purchase warrants and broker warrants. "The exercise of the warrants," states CEO Iris Bincovich, "Indicates that investors are confident in... Read More

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC PINK: INNPF) (the " Company " or " Innocan "), is pleased to announce today a successful manufacturing demonstration of liposome platform technology (" LPT ") CBD-loaded Liposomes under aseptic conditions, together with the Hebrew University of Jerusalem. This is an important milestone in the production process of CBD-loaded Liposomes, as it now permits the demonstration... Read More